CD109 anticorps

N° du produit ABIN7865575

Cet anticorps anti-CD109 Monoclonal Souris (Clone EBS-CD-046) (ABIN7865575) détecte spécifiquement CD109 dans IHC, ICC, FACS et IF. L’anticorps est réactif avec des échantillons de Humain et Singe.

Aperçu rapide pour CD109 anticorps (ABIN7865575)

Antigène: CD109

Reactivité: Humain, Singe

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp CD109 est non-conjugé

Application: Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FACS), Immunofluorescence (IF)

Clone: EBS-CD-046

Détail du produit anti-CD109 anticorps

Fonction: anti-CD109 mouse monoclonal, EBS-CD-046, purified

Purification: affinity chromatography

Immunogène: recombinant human CD109

Isotype: IgG2a kappa

Information d'application

Indications d'application:

ICC/IF_dilution: 1:100-1:200 (0.5-1.0 μg/mL)

FACS_dilution: 0.5-1.0 μg/million cells in 0.1 ml

IHC-frozen_dilution: 1:50-1:100 (1-2 μg/mL)

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 100 μg/mL

Buffer: PBS with 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: store at 2 - 8 °C

Détails sur CD109

Antigène: CD109

Autre désignation: CD109

Sujet: CD109 is a GPI-anchored member of the alpha-2-macroglobulin (A2M) and complement family of proteins. It is expressed on activated T-cells, platelets, hematopoietic stem cells, megakaryocyte precursors, vascular endothelial cells, basal and myoepithelial cells of secretory glands, and squamous cell carcinomas. A 170-180 kDa precursor is autocatalytically reduced to 150 kDa and 120 kDa forms. On keratinocytes CD109 binds TGF-beta and associates with TGF-beta RI and TGF-beta RII, resulting in inhibition of TGF-beta signalling. Polymorphisms of CD109 include the platelet-specific Gov antigen and the blood group ABH antigens. Alloantibodies directed against these antigens result in unsuccessful platelet transfusions, neonatal alloimmune thrombocytopenia, and post-transfusion purpura. Positive control: Human platelets, blood vessels.

Pathways: Activated T Cell Proliferation